Patients with neurological systems of COVID-19 six times more likely to die in hospital
Patients with clinically diagnosed neurological symptoms associated with COVID-19 are six times more likely to die in the hospital than those without the neurological complications, according to an interim analysis from the Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID), according to a news release from UPMC.
A paper published in JAMA Network Open presents early results of the global effort to gather information about the incidence, severity and outcomes of neurological manifestations of COVID-19 disease.
“Very early on in the pandemic, it became apparent that a good number of people who were sick enough to be hospitalized also develop neurological problems,” said lead author Sherry Chou, MD, MSc, Principal Investigator of the Consortium and Associate Professor of Critical Care Medicine, Neurology, and Neurosurgery at the University of Pittsburgh School of Medicine and UPMC. “A year later, we are still fighting an unknown invisible enemy and, like in any battle, we need intel — we have to learn as much as we can about neurological impacts of COVID-19 in patients who are actively sick and in survivors.”
According to UPMC, the GCS-NeuroCOVID is the largest cohort study of neurological manifestations of COVID-19 to date, spanning 133 adult patient sites in all continents except Antarctica.
Among one group of 3,744 hospitalized adult patients with COVID-19, 82% had self-reported or clinically captured neurological symptoms. Nearly 4 out of 10 patients reported having headaches, and approximately 3 out of 10 said they lost their sense of smell or taste. Of the clinically diagnosed syndrome — abnormalities that a bedside clinician can observe, regardless of whether the patient is aware of the problem — acute encephalopathy was most common, affecting nearly half of the patients, followed by coma (17%) and strokes (6%).
Despite early concerns about the coronavirus’s ability to directly attack the brain and cause brain swelling and inflammation — meningitis and encephalitis — those events were very rare, occurring in less than 1% of hospitalized COVID-19 patients.
The researchers analyzed data from three different types of patient cohorts — the “all COVID-19” cohort, which included all 3,055 hospitalized patients with COVID-19, irrespective of their neurological status; the “neurological” cohort, which included 475 hospitalized COVID-19 patients with clinically confirmed neurological symptoms compiled by the GCS-NeuroCOVID Consortium; and the “ENERGY” cohort, or 214 hospitalized COVID-19 patients who required evaluation by a consulting neurologist and provided consent to participate in the European Academy of Neurology Neuro-COVID Registry (ENERGY), a formal partner of the GCS-NeuroCOVID Consortium.
The study found that having a preexisting neurological condition of any kind—from brain, spinal cord and nerve diseases to chronic migraines, dementia or Alzheimer’s disease, among others — is the strongest predictor of developing COVID-19-related neurological complications, increasing the risk by two-fold. In addition, having any neurological symptoms related to COVID-19 — from something as seemingly innocuous as the loss of smell to major events like strokes — is associated with a six-fold higher risk of dying.
But even if a patient beats the odds and recovers, their long-term health outlook is still uncertain.
